Boothbay Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $398K | Hold |
22,997
| – | – | 0.01% | 822 |
|
|
2025
Q1 | $503K | Buy |
+22,997
| New | +$503K | 0.01% | 705 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 1310 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 1402 |
|
|
2024
Q2 | – | Sell |
-24,825
| Closed | -$1.46M | – | 1335 |
|
|
2024
Q1 | $1.46M | Buy |
24,825
+12,169
| +96% | +$715K | 0.03% | 519 |
|
|
2023
Q4 | $758K | Buy |
12,656
+4,806
| +61% | +$288K | 0.02% | 689 |
|
|
2023
Q3 | $299K | Sell |
7,850
-19,344
| -71% | -$736K | 0.01% | 1069 |
|
|
2023
Q2 | $2.48M | Buy |
27,194
+6,136
| +29% | +$559K | 0.05% | 369 |
|
|
2023
Q1 | $1.39M | Buy |
+21,058
| New | +$1.39M | 0.03% | 699 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 1728 |
|
|
2022
Q3 | – | Sell |
-5,065
| Closed | -$229K | – | 1930 |
|
|
2022
Q2 | $229K | Buy |
+5,065
| New | +$229K | 0.01% | 1411 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 1874 |
|
|
2021
Q4 | – | Sell |
-34,671
| Closed | -$1.14M | – | 1668 |
|
|
2021
Q3 | $1.14M | Buy |
+34,671
| New | +$1.14M | 0.03% | 561 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 1662 |
|
|
2020
Q2 | – | Sell |
-9,448
| Closed | -$253K | – | 825 |
|
|
2020
Q1 | $253K | Buy |
+9,448
| New | +$253K | 0.02% | 520 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 742 |
|
|
2019
Q1 | – | Sell |
-26,000
| Closed | -$343K | – | 645 |
|
|
2018
Q4 | $343K | Buy |
+26,000
| New | +$343K | 0.05% | 281 |
|